Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 09:09pm CEST
   By Peter Loftus 
 

Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)), which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.

Teva's petition is aimed at Biogen Idec Inc. (>> Biogen Idec Inc.), which expects an FDA decision by late March on Biogen's application to market a new MS treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.

In a Dec. 31 citizen petition to the FDA, Teva asked the agency not to approve any new MS drugs until the agency refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.

Teva said it was important for the agency to hear outside advisers' evaluations of any safety risks, in light of risks that have emerged after MS treatments were approved in recent years, including Biogen's own Tysabri MS treatment. Tysabri was removed from the market soon after its 2004 introduction after some recipients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.

Teva said in its petition that BG-12 "may be associated with other serious safety risks" including the potential risk for kidney-related problems.

Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition.

Biogen spokeswoman Kate Niazi-Sai said the company is confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track.

Results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo. There were no cases of kidney failure classified by researchers as serious adverse events, according to the article.

RBC Capital Markets analyst Shibani Malhotra, who reported the Teva citizen petition in a research note earlier Wednesday, said it may not pose a big obstacle for BG-12's approval because a similar drug has been available as a psoriasis treatment in Europe, and serious safety issues haven't emerged.

RBC analyst Michael Yee said he still expects the FDA to approve BG-12 by the targeted action date in late March.

On Monday at the J.P. Morgan Healthcare conference in San Francisco, Biogen Chief Executive George Scangos defended the experimental MS pill. He acknowledged there has been some chatter about BG-12 safety, but chalked this up to competitors marketing against the product.

"We're very confident in the safety," he said. "I kind of take it as a compliment that the competition is worried about BG-12."

Teva spokeswoman Denise Bradley said the petition was intended to bring to light important points "to protect the safety of patients." Teva wants to ensure "that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile" for any new MS drug, she said.

FDA spokeswoman Sandy Walsh said the agency will review the petition.

--Jon Kamp contributed to this article.

-Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN 1.45% 283.75 Delayed Quote.-12.84%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.80% 7600 Delayed Quote.16.51%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09:34pTEVA PHARMACEUTICAL INDUSTRIES : FDA to respond to Teva migraine drug applicatio..
AQ
02:07pTEVA PHARMACEUTICAL INDUSTRIES : Confirms September PDUFA Date for Fremanezumab
BU
05/21ACTELION : Teva on FDA name and shame list
AQ
05/21TEVA PHARMACEUTICAL INDUSTRIES : Israel’s Teva on FDA blacklist of drugmak..
AQ
05/18TEVA PHARMACEUTICAL INDUSTRIES : CORRECTING and REPLACING Teva Announces Publica..
PU
05/18TEVA PHARMACEUTICAL INDUSTRIES LTD ( : Free Stock Performance Review on Teva Pha..
AC
05/18FDA approves Aimovig as first CGRP inhibitor for migraines
AQ
05/18Hikma reaffirms full-year revenue forecast, cites better generics business
RE
05/17BERKSHIRE HATHAWAY : Buffett's Berkshire Hathaway doubles its stake in Teva
AQ
05/16BERKSHIRE HATHAWAY : Buffett's Berkshire Hathaway doubles its stake in Teva
AQ
More news
News from SeekingAlpha
05/22Antares Pharma, Excellent Risk-Reward Profile 
05/22CORE BIOTECH BUYS #16 : Taking Advantage Of Weakness To Add To Conviction Ideas 
05/21Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will Tha.. 
05/21VALEANT PHARMACEUTICALS : Worth At Least $30 
05/18Amgen's first mover advantage with Aimovig bodes well - analysts 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,10x
Capi. / Sales 2019 1,10x
Capitalization 21 502 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target -13%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED16.51%21 502
JOHNSON & JOHNSON-11.45%329 663
PFIZER-1.16%208 947
NOVARTIS-6.55%201 263
ROCHE HOLDING LTD.-8.90%194 670
MERCK AND COMPANY3.87%157 248